Co‑expressing mitochondrially targeted antioxidant enzymes with optogenetic opsins mitigates activity‑induced oxidative stress to prolong inner retinal survival in degeneration

Mei Mensah· Mar 25, 2026

Mechanism: Co-expressing mitochondria-targeted catalase (mCAT) with optogenetic opsin MCO-010 scavenges light-induced mitochondrial ROS in retinal neurons. Readout: Readout: This reduces inner retinal remodeling, leading to a 30% preservation of retinal thickness and a 0.2 logMAR functional visual gain over 6 months.

Hypothesis

Co expressing a mitochondria targeted catalase with the multi characteristic opsin MCO 010 in inner retinal neurons reduces light driven calcium influx induced ROS production thereby slowing inner retinal remodeling and preserving visual function longer than MCO 010 alone.

Rationale

Optogenetic strategies currently act as a replacement bypassing dead photoreceptors [1] [2]. Chronic depolarization of ganglion or bipolar cells by microbial opsins raises intracellular Ca2+ which can activate calpains and NADPH oxidase leading to oxidative stress [4]. Inner retinal remodeling neurite sprouting Müller gliosis synaptic rewiring worsens over time and limits the therapeutic window [2]. Mitochondrial ROS are a key driver of this remodeling [5]. Targeting catalase to mitochondria scavenges H2O2 at its source protecting both the organelle and downstream signaling pathways. Combining mCAT with an opsin that restores light responsiveness should therefore decouple visual gain from oxidative damage.

Experimental Design

Use rd10 mice (model of rapid photoreceptor loss) at P14 before significant inner retinal changes. Subretinal AAV dual vector system: one vector carries MCO 010 under a CAG promoter the other carries mCAT fused to a mitochondrial targeting signal (COX8) under the same promoter; control groups receive MCO 010 + GFP or AAV GFP alone. Verify expression and localization by immunohistochemistry and western blot at 4 weeks. Longitudinal assessments over 6 months:

Spectral domain OCT for inner nuclear layer (INL) and ganglion cell layer (GCL) thickness.
Full field ERG to monitor residual photoreceptor and inner retinal responses.
Behavioral optomotor assay for visual acuity and contrast sensitivity.
ROS detection using MitoSOX labeling in retinal sections.
Glial activation (GFAP Iba1) scoring. Sample size n = 10 per group powered to detect 15 % thickness difference (alpha = 0.05 beta = 0.2).

Predicted Outcomes

MCO 010 + mCAT eyes will show significantly less INL and GCL thinning than MCO 010 alone (approx 30 % preservation vs approx 10 %). ERG b wave amplitudes will remain higher indicating better inner retinal signal transmission. Optomotor thresholds will stay above baseline for longer translating to a functional gain of at least 0.2 logMAR over controls. MitoSOX fluorescence will be reduced by about 40 % in the inner retina correlating with lower GFAP/Iba1 scores. No increase in inflammatory infiltrate beyond baseline suggesting that antioxidant expression does not exacerbate immunogenicity.

Potential Pitfalls

Over expression of catalase could disrupt H2O2 dependent signaling pathways needed for normal plasticity; titrating expression via a self regulating promoter (e.g ARE driven) may be necessary. Dual vector AAV may lead to uneven co expression; using a single bicistronic vector with a P2A peptide could improve stoichiometry. Long term immune response to the mitochondrial targeting sequence remains unknown; inclusion of a transient corticosteroid regimen as used in current trials [4] can mitigate early inflammation.

If the hypothesis holds it would shift optogenetics from a pure replacement strategy to a hybrid neuroprotective optogenetic approach extending therapeutic benefit beyond mere light perception.